@phdthesis{Gotthard2023,
  author    = {Gotthard, Hannes},
  title     = {Targeting Colorectal Cancer Stem Cells with Hemibodies},
  doi       = {10.25972/OPUS-30309},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-303090},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2023},
  abstract  = {The cancer stem cell hypothesis is a cancer development model which elicited great interest in the last decades stating that cancer heterogeneity arises from a stem cell through asymmetrical division. The Cancer Stem Cell subset is described as the only population to be tumorigenic and having the potential to renew. Conventional therapy often fails to eradicate CSC resulting in tumor relapse. Consequently, it is of great inter-est to eliminate this subset of cells to provide the best patient outcome. In the last years several approaches to target CSC were developed, one of them being immunotherapeu-tic targeting with antibodies. Since markers associated with CSC are also expressed on normal stem cells or healthy adjacent tissue in colorectal cancer, dual targeting strate-gies are preferred over targeting only a single antigen. Subsequently, the idea of dual targeting two CSC markers in parallel by a newly developed split T cell-engaging anti-body format termed as Hemibodies emerged. In a preliminary single cell RNA sequenc-ing analysis of colorectal cancer cells CD133, CD24, CD166 and CEA were identified as suitable targets for the combinatorial targeting strategy. Therefore, this study focused on trispecific and trivalent Hemibodies comprising a split binding moiety against CD3 and a binding moiety against either CD133, CD24, CD166 or CEA to overcome the occurrence of resistance and to efficiently eradicate all tumor cells including the CSC compartment. The study showed that the Hemibody combinations CD133xCD24, CD133xCD166 and CD133xCEA are able to eliminate double positive CHO cells with high efficacy while having a high specificity indicated by no killing of single antigen positive cells. A thera-peutic window ranging between one to two log levels could be achieved for all combina-tions mentioned above. The combinations CD133xCD24 and CD133xCD166 further-more proved its efficacy and specificity on established colorectal cancer cell lines. Be-sides the evaluation of specificity and efficacy the already introduced 1st generation of Hemibodies could be improved into a 2nd generation Hemibody format with increased half-life, stability and production yield. In future experiments the applicability of above-mentioned Hemibodies will be proven on patient-derived micro tumors to also include variables like tumor microenvironment and infiltration.},
  subject      = {Monoklonaler bispezifischer Antik{\"o}rper},
  language  = {en}
}
@phdthesis{Feldmann2002,
  author    = {Feldmann, Kristina},
  title     = {Signal transduction of transforming growth factor-Beta in cytotoxic T cells},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-4912},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2002},
  abstract  = {Transforming-Growth-Factor-beta1 (TGF-b1) ist ein multifunktionelles Zytokin, welches insbesondere Zellwachstum und Zelldifferenzierung koordiniert. TGF-b ist vor allem daf{\"u}r bekannt, Zellen des Immunsystems zu beeinflussen. TGF-b steuert zum Beispiel die Differenzierung von T-Zellen und und deren Effektorfunktionen. Die Signaltransduktion von TGF-b wird vermittelt durch die Phosphorylierung von Rezeptor-assoziierten Smad-Proteinen (R-Smads). R-Smads werden vom Typ I Rezeptor aktiviert, der seinerseits vom hochaffinen Typ II Rezeptor phosphoryliert wird, sobald der Ligand bindet. Die phosphorylierten RSmads assoziieren darauf mit Co-Smads. Heterooligomere von R-Smads und Co-Smads wandern dann in den Zellkern, wo sie im Zusammenspiel mit Transkriptionsfaktoren wie CBP/p300 oder AP-1 die Transkription TGF-b-spezifischer Zielgene koordinieren. Neue Erkenntnisse lassen vermuten, daß die pleiotropen Effekte von TGF-b durch das Interagieren mit anderen Signalkaskaden entstehen, zum Beispiel mit dem MAP-Kinase-Weg oder der STAT-Kaskade. Wir beschreiben hier den Effekt von TGF-b auf die Effektorfunktionen unterschiedlich stimulierter prim{\"a}rer Maus-Milzzellen und aufgereinigten zytotoxischen CD8+ Maus-TZellen. Langzeitbehandlung mit TGF-b resultierte in der Unf{\"a}higkeit der Zellen, Smad2 ligandeninduziert zu phosphorylieren. Entweder wurde {\"u}berhaupt keine Phosphorylierung beobachtet, oder eine anhaltende Phosphorylierung von Smad2 unabh{\"a}ngig vom Vorhandensein des Liganden. Des weiteren stellten wir einen Zusammenhang zwischen anhaltender Smad2-Phosphorylierung und der Resistenz gegen{\"u}ber TGF-b induzierter Wachstumshemmung fest. Im Gegensatz dazu zeigen Zellen, die sensitiv sind gegen{\"u}ber TGF-b vermittelter Wachstumshemmung, keine Smad2-Phosphorylierung mehr. Bez{\"u}glich ihrer zytotoxische Aktivt{\"a}t waren allerdings beide Ph{\"a}notypen nicht mehr lytisch wirksam, unabh{\"a}ngig von der jeweiligen Smad2-Phosphorylierung. In dieser Arbeit zeigen wir auch die Notwendigkeit eines funktionalen MEK-1-Signalweges auf, der unabdingbar ist, damit TZellen keine Wachstumsinhibierung durch TGF-b mehr erfahren. Das Blockieren dieses Signalweges f{\"u}hrt dar{\"u}berhinaus bei diesen Zellen ebenfalls zu einem ver{\"a}nderten Smad2- Phosphorylierungsmuster. Bez{\"u}glich des JNK-Signalweges konnten wir feststellen, daß ein funktional aktiver JNK-Signalweg mit der Resistenz gegen{\"u}ber TGF-b vermittelter Wachstumsinhibierung einhergeht. Allerdings f{\"u}hrt die Zugabe von IFNg und/oder aCD28- Antik{\"o}rper nicht zu einer ver{\"a}nderten Sensitivit{\"a}t gegen{\"u}ber TGF-b. Im Gegensatz zuprim{\"a}ren Zellen k{\"o}nnen die beschriebenen Zusammenh{\"a}nge in Zellkulturen vom humanen und murinen T Zellen nicht beobachtet werden, und sind somit spezifisch f{\"u}r primare TZellen. Wir beschreiben auch die Klonierung eines chim{\"a}ren dominant-negativen Typ II Rezeptors, der an eine Kinase gekoppelt ist, die bei Aktivierung Zelltod ausl{\"o}st. Damit soll es in Zukunft m{\"o}glich sein, T-Zellen gegen{\"u}ber TGF-b Resistenz zu verleihen. Die hier geschilderten Ergebnisse vertiefen die Kenntnisse {\"u}ber molekulare Mechanismen der Wirkung von TGF-b auf T-Zellen und k{\"o}nnen vielleicht dazu beitragen, negative Effekte von TGF-b, zum Beispiel in der Tumortherapie, gezielt abzuwenden.},
  subject      = {T-Lymphozyt},
  language  = {en}
}
@phdthesis{Groh2013,
  author    = {Groh, Janos Michael},
  title     = {Pathogenic impact of immune cells in mouse models of neuronal ceroid lipofuscinosis},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-77684},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2013},
  abstract  = {The neuronal ceroid lipofuscinoses (NCLs) are fatal neurodegenerative disorders in which the visual system is affected in early stages of disease. A typical accompanying feature is neuroinflammation, the pathogenic impact of which is presently unknown. In this study, the role of inflammatory cells in the pathogenesis was investigated in Palmitoyl-protein thioesterase 1-deficient (Ppt1-/-) and Ceroidlipofuscinosis, neuronal 3-deficient (Cln3-/-) mice, models of the infantile and juvenile forms of NCL, respectively. Focusing predominantly on the visual system, an infiltration of CD8+ cytotoxic Tlymphocytes and an activation of microglia/macrophage-like cells was observed early in disease. To analyze the pathogenic impact of lymphocytes, Ppt1-/- mice were crossbred with mice lacking lymphocytes (Rag1-/-) and axonal transport, perturbation and neuronal survival were scored. Lack of lymphocytes led to a significant amelioration of neuronal disease and reconstitution experiments revealed a crucial role of CD8+ cytotoxic T-lymphocytes. Lack of lymphocytes also caused an improved clinical phenotype and extended longevity. To investigate the impact of microglia/macrophage-like cells, Ppt1-/- and Cln3-/- mice were crossbred with mice lacking sialoadhesin (Sn-/-), a monocyte lineage-restricted cell adhesion molecule important for interactions between macrophage-like cells and lymphocytes. Similar to the lack of lymphocytes, absence of sialoadhesin significantly ameliorated the disease in Ppt1-/- and Cln3-/- mice. Taken together, both T-lymphocytes and microglia/macrophage-like cells were identified as pathogenic mediators in two distinct forms of fatal inherited neurodegenerative storage disorders. These studies expand the concept of secondary inflammation as a common pathomechanistic feature in some neurological diseases and provide novel insights that may be crucial for developing treatment strategies for different forms of NCL.},
  subject      = {Nervendegeneration},
  language  = {en}
}
@phdthesis{Visan2003,
  author    = {Visan, Ion Lucian},
  title     = {P0 specific T-cell repertoire in wild-type and P0 deficient mice},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-5734},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2003},
  abstract  = {Zusammenfassung Das Myelinprotein P0 stellt eine zentrale Komponente f{\"u}r die Stabilit{\"a}t und Funktionalit{\"a}t der Myelinscheiden des peripheren Nervensystems dar. Mutationen des P0-Proteins f{\"u}hren zu verschiedenen, schwer behindernden peripheren Neuropathien wie der Charcot-Marie-Tooth- oder der Dejerine-Sotas-Erkrankung. Wir haben das Tiermodell der P0-Knock-Out-M{\"a}use verwendet, um im Vergleich zu den C57BL/6-Wildtyp-Tieren Selektionsmechanismen des P0-spezifischen T-Zell-Repertoires zu untersuchen. Dazu wurde eine Reihe von {\"u}berlappenden 20-mer-Peptiden benutzt, die die gesamte Aminos{\"a}uresequenz von P0 abdeckten. Mit Hilfe dieser Peptide wurde ein sog. „Epitop-Mapping" der H2-Ab-restringierten T-Zell-Antwort durchgef{\"u}hrt. Auf diese Weise konnte das P0-Peptid 5 (Aminos{\"a}ure 41-60) in der extrazellul{\"a}ren P0-Dom{\"a}ne als immunogene Determinante identifiziert werden. Dieses immunogene Peptid wurde dann f{\"u}r Untersuchungen der Toleranzmechanismen verwendet und zeigte, dass in P0-Knock-Out-M{\"a}usen ein hochreaktives P0-spezifisches T-Zell-Repertoire vorliegt, w{\"a}hrend es in Wildtyp-Tieren inaktiviert ist und so Selbsttoleranz erzeugt wird. Die Toleranzerzeugung in Wildtyp- und heterozygoten P0 +/- M{\"a}usen h{\"a}ngt nicht von der Gen-Dosis ab. P0 ist ein gewebespezifisches Antigen, dessen Expression normalerweise auf myelinisierende Schwann-Zellen beschr{\"a}nkt ist. Die klassischen Vorstellungen zu Toleranzmechanismen gegen{\"u}ber gewebsspezifischen Antigenen schrieben diese vor allem peripheren Immunmechanismen zu. Durch den erstmaligen Nachweis von intrathymischer Expression gewebsspezifischer Antigene wie P0 konnten wir best{\"a}tigen, dass f{\"u}r P0 offensichtlich die Expression deutlich weiter verbreitet ist, insbesondere auch auf Thymus-Stroma-Zellen. Unter Verwendung von Knochenmarkschim{\"a}ren haben wir weitere Untersuchungen durchgef{\"u}hrt, wie Knochenmarks-abstammende Zellen im Vergleich zu nicht-h{\"a}matopoetischen Zellen Toleranz gegen{\"u}ber P0 erzeugen k{\"o}nnen. Unsere Befunde zeigen, dass Knochenmarks-abh{\"a}ngige Zellen nicht ausreichen, um v{\"o}llige Toleranz zu erzeugen. Zus{\"a}tzlich wurde eine P0-Expression auf anderen Geweben wie dem Thymus ben{\"o}tigt, um komplette Toleranz zu erhalten. Wir identifizierten ein kryptisches P0-Peptid 8 und zwei subdominante P0-Peptide 1 und 3. W{\"a}hrend das Peptid 8 sowohl in Wildtyp- als auch Knock-Out-M{\"a}usen erkannt wurde, wurden die Peptide 1 und 3 in Wildtyp-M{\"a}usen nicht als Immunogen erkannt. Die genannten Peptide wurden verwendet, um eine experimentelle autoimmune Neuritis (EAN) zu erzeugen. Mit keinem der experimentellen Ans{\"a}tze konnten wir klinische Zeichen einer EAN generieren, allerdings mit dem Peptid 3 doch Entz{\"u}ndung im peripheren Nerven beobachten. Es werden zuk{\"u}nftig weitere Untersuchungen ben{\"o}tigt, um P0-spezifische T-Zell-Linien zu etablieren und so mit h{\"o}herer Effizienz eine EAN zu erzeugen. Unsere Untersuchungen sprechen daf{\"u}r, dass bei gentherapeutischen Ans{\"a}tzen bei erblichen Neuropathien vorsichtig und schrittweise vorgegangen werden muss, da mit sekund{\"a}rer Autoimmunit{\"a}t und damit Inflammation im peripheren Nerven zu rechnen ist.},
  subject      = {Myelin},
  language  = {en}
}
@phdthesis{Akimzhanov2005,
  author    = {Akimzhanov, Askar M.},
  title     = {Epigenetic repression of the NFATc1 transcription factor in human lymphomas},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-12921},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2005},
  abstract  = {We examined the regulation of NFATc1 in different lymphomas and observed an inversed correlation between the methylation status and expression of NFATc1. Our data demonstrate that aberrant DNA methylation associated with chromatin remodeling within nfatc1 locus is a major mechanism for the repression of NFATc1 expression, suggesting that the DNA methylation-mediated transcriptional silencing of NFATc1 may be a critical event in the tumorogenesis of ALCLs and cHLs. Furthermore, the DNA methylation of human nfatc1 promoter region could be used as a novel biomarker of tumor progression. Our results indicate a close link between the loss of immunoreceptor signaling and NFATc1 expression in human lymphomas. For both ALCLs and cHLs, defects in immunoreceptor signaling have been described which result in a loss of receptor-mediated gene expression programs (Schwering et al., 2003; Bonzheim et al., 2004; Marafioti et al., 2004). In T cells, one indicator gene of these programs appears to be the nfatc1 gene whose expression is controlled by TCR signals (Chuvpilo et al., 2002a). In contrast, in T cells NFATc1 expression is unaffected by TCR signals, and NFATc2 was found to be expressed at normal levels in ALCLs and cHLs (L.K., unpubl. data). Moreover, the activity of NF-kappaB factors which can bind to certain NFAT binding sites and share a distantly-related DNA binding domain with NFATs is strongly elevated in cHL cells (Bargou et al., 1997; Hinz et al., 2001; Hinz et al., 2002) suggesting that NFATs and NF-kappaBs exert very different effects on generation and maintenance of Hodgkin's lymhomas. However, it should be mentioned that in Burkitt's and further B cell lymphomas in which NFATc1 proteins are strongly expressed and controlled by receptor signals (Kondo et al., 2003), they could exert a promoting function in tumor development. The genes of p53 family members p63 and p73 are prominent examples for mammalian genes whose products can act both as oncoproteins and tumor suppressor genes (Hibi et al., 2000; Stiewe and Putzer, 2002), and it is likely that more genes exist which encode both tumor suppressors and oncoproteins. It remains to be shown whether the nfatc1 gene is one of them.},
  subject      = {Lymphom},
  language  = {en}
}
@phdthesis{Foeger2000,
  author    = {F{\"o}ger, Niko},
  title     = {Costimulatory function of CD44},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-1186},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2000},
  abstract  = {T cell activation is supposed to require two signals via engagement of the TCR and a costimulatory molecule. However, the signaling cascade of costimulatory molecules has remained elusive. Here, I provide evidence that CD44 supports proliferation as well as apoptosis mainly, if not exclusively, by enhancing signal transduction via the TCR/CD3 complex. Blockade of CD44 interferes with mounting of an immune response. This has been demonstrated by the significantly decreased IL-2 production of a T helper line, when stimulated in the presence of a competing CD44 receptor globulin. To evaluate the underlying mechanism, CD44 was cross-linked by an immobilized antibody (IM7). Cross-linking of CD44 induces proliferation of peripheral T cells and apoptosis of thymocytes and a T helper line in the presence of subthreshold levels of anti-CD3. CD44-induced proliferation was accompanied by an upregulation of the activation markers CD25 and CD69 and an increased cytokine production. TCR-mediated apoptosis was accompanied by an upregulation of CD95 ligand and CD95 receptor, which could be greatly enhanced by costimulation via CD44. On the level of signal transduction, coligation of CD44 with CD3 resulted in a strong and sustained increase of early tyrosine phosphorylation events and upregulated downstream signal transduction pathways, such as the ras/ERK and the JNK signaling cascades. These pleiotropic effects of CD44 are due to its involvement in the most proximal events in TCR signaling, as demonstrated by a strong increase in the phosphorylation of the TCR z-chain and ZAP-70. Notably, cross-linking of CD44 was binding-site dependent and was only effective when supporting colocalization of the TCR/CD3 complex and CD44. Cross-linking of CD44 via immobilized IM7 also induced profound changes in cell morphology, characterized by strong adhesion, spreading and development of surface extensions, which were dependent on a functional tubulin and actin cytoskeleton. These cytoskeletal rearrangements were mediated by rac1, a small GTPase of the rho subfamily, and src-family kinases, two of which, fyn and lck, were found to be associated with CD44. By cross-linkage of CD44 these kinases were redistributed into so called lipid rafts. It is supposed that for T cell activation a relocation of the TCR/CD3 complex into the same membrane microdomains is required. The data are interpreted in the sense that the costimulatory function of CD44 relies on its cooperativity with the TCR. Most likely by recruitment of phosphokinases CD44 significantly lowers the threshold for the initiation of signaling via the TCR. The requirement for immobilized anti-CD44, the necessity for neighbouring anti-CD3 and the dependence on the binding site of CD44 strongly suggest that the costimulatory mechanism involves cytoskeletal rearrangements, which facilitate recruitment and redirection of src-family protein kinases in glycolipid enriched membrane microdomains.},
  subject      = {Antigen CD44},
  language  = {en}
}
@phdthesis{Lee1999,
  author    = {Lee, Kyeong-Hee},
  title     = {Cofilin},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-1681},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {1999},
  abstract  = {This study has identified cofilin, an actin binding protein, as a control element in the reorganization of the actin cytoskeleton which is highly relevant for T lymphocyte activation. Cofilin is regulated in its activity by reversible phosphorylation which is inducible by stimulation through accessory receptors such as CD2 and CD28. First it could be demonstrated that accessory receptor triggering induces the transient association of cofilin with the actin cytoskeleton and that only the dephosphorylated form of cofilin possesses the capacity to bind cytoskeletal actin in vivo. PI3-kinase inhibitors block both the dephosphorylation of cofilin and its association with the actin cytoskeleton. Importantly, cofilin, actin, PI3-kinase and one of its substrates, namely phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) which can bind to cofilin, co-localize within CD2-receptor caps. The cofilin/F-actin interaction has been identified as a crucial regulatory element for receptor cap formation and the strength of signal transduction. To this end, appropriately designed cell permeable non-toxic peptides that are homologous to actin binding motifs of the human cofilin sequence were introduced into untransformed human peripheral blood T lymphocytes. These peptides competitively and dose dependently inhibit the activation induced interaction of cofilin with the actin cytoskeleton in vivo. By this approach it was possible to study, for the first time, the functional consequences of this interaction in immunocompetent T cells. The present data demonstrate that inhibition of the actin/cofilin interaction in human T lymphocytes by means of these cofilin derived peptides abolishes receptor cap formation and strongly modulates functional T cell responses such as T cell proliferation, interleukin-2 production, cell surface expression of CD69, gIFN production, and CD95L expression. Importantly, receptor independent activation by PMA and calcium ionophore circumvents these peptide produced inhibitory effects on lymphocyte stimulation and places the cofilin/actin interaction to a proximal step in the cascade of signaling events following T cell activation via surface signals. The present results are novel since as yet no information existed regarding the molecular elements which link cell surface receptor stimulation directly to the resulting reorganization of the actin cytoskeleton.},
  subject      = {T-Lymphozyt},
  language  = {en}
}
@phdthesis{Hauff2009,
  author    = {Hauff, Cornelia},
  title     = {Aspects of the mode of action of bispecific T cell engager (BiTE) antibodies},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-48369},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2009},
  abstract  = {Bispecific T cell engager (BiTE) display a novel design among the class of bispecific antibodies and hold great promise to fight diverse cancers. BiTE molecules consist of two different binding entities derived from two human IgG antibodies connected by a short peptide linker. Their binding arms are directed against the CD3e chain of the T cell receptor on T cells and against an antigen that is specific for (e.g., CD19 for lymphoma in MT103) or over-expressed on (e.g., EpCAM for epithelial cancer in MT110) tumor cells. Without requirement for pre- or co-stimulation, BiTE molecules efficiently redirect CD3+ T cells towards tumor cells expressing the relevant target antigen. Only a BiTE molecule simultaneously bound to both tumor cell and T cell activates the T cell to exert its cytolytic function resulting in tumor cell death. In T cells stimulated with both BiTE and target cells, elevated levels of caspase activation and increased expression of cytotoxic and signaling proteins are observed. These include cytolytic proteins granzyme B and perforin, activation markers CD69 and CD25 and adhesion molecules CD2 and LFA-1. Activated T cells secrete the usual mix of cytokines, among them pro-inflammatory cytokines IFN-g and TNF-a. The membrane of tumor cells expressing the relevant target antigen is perforated during the attack of BiTE-stimulated effector cells as can be concluded from adenylate kinase release from the cytosol of tumor cells. Ca2+-chelator EGTA completely blocked BiTE-mediated activation of caspases and tumor cell lysis. As perforin is strictly Ca2+-dependent, a major role for this pore-forming protein is assumed for the elimination of tumor cells via BiTE-stimulated T cells. Granzyme B and caspases are main players in BiTE-mediated elimination of tumor cells. Inhibitors of granzyme B or caspases reduce or block, respectively the activation of caspases. However, other signals of apoptosis (cleavage of PARP and fragmentation of DNA) were only reduced by granzyme B inhibitor or caspase inhibitor. Most interestingly, the lytic capacity of BiTE molecules was not impaired by granzyme B inhibitor or caspase inhibitor. It seems that there is no requirement for granzyme B and caspases to be present simultaneously. Instead the data presented provide evidence that they can be replaced one at a time by related proteins. Pre-incubation of effector cells with the glucocorticoids dexamethasone or methylprednisolone resulted in markedly decreased secretion of cytokines by T cells yet only a small reduction in the expression of activation markers and adhesion molecules on T cells and specific lysis of tumor cells upon BiTE stimulation. Soluble factors secreted in an undirected manner by BiTE-stimulated T cells do not mediate tumor cell death by themselves. Bystander cells negative for the antigen that is recognized by the BiTE molecule will not be compromised by BiTE activity. The cytokine TGF-b reduced proliferation as well as granzyme B and perforin expression of BiTE-stimulated T cells. Redirected lysis by BiTE-activated T cells was also decreased under the influence of TGF-b, however lysis was still performed at a reasonable rate (72 \% of target cells). TGF-b does not exert a deleterious effect on lytic potential of BiTE-stimulated T cells. The minimal anticipated biological effect level for the BiTE MT110 was determined for the entry of MT110 into phase I clinical studies. Experiments analyzing redirected lysis of tumor cells, expression of activation marker CD25 and cytokine release by T cells revealed a MABEL value of 50 pg/ml for MT110.},
  subject      = {Antik{\"o}rper},
  language  = {en}
}
@article{DuschlJahnBertlingetal.1992,
  author    = {Duschl, Albert and Jahn, Ute and Bertling, Claudia and Sebald, Walter},
  title     = {A comparison of assays for the response of primary human T-cells upon stimulation with interleukin-2, interleukin-4 and interleukin-7},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-86750},
  year      = {1992},
  abstract  = {The most commonly used assay to quantitate the response of peripheral T~cells upon stimulation with growth factors is determination of incorporated (JH]TdR. We compared thls test to three other methods: 1. direct countlog of cells with a Coulter type counter as reference assay, 2. a colorimetric assay using the tetrazolium dye 3-[ 4,S-dimethylthiazol-l-yl]-2,5diphenyl tetrazolium (MTT), which is a cheap and increasingly popular non-radioactive method and 3. incorporation of the thymidine analog 5-bromo-2'-deoxyuridine detection with a monoclonal antibody on cytospins. Primary human PHA-blasts from >30 healthy individuals were stimulated with IL-2, IL-4 aod IL-7 and assayed with up to four different methods. We discuss the advantages and disadvantages of the assays used and tbe effects of differences between cell preparations. We observed no significant variations between individuals for the dose dependence, but the relative emctency of IL4 compared to IL-2 and IL-7 was variable. This was probably due to the slower response observed upon stimulation with this factor.},
  subject      = {T-Lymphozyt},
  language  = {en}
}